Senores Pharmaceuticals Ltd (SENORES) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039497, "name": "Senores Pharma.", "stock_name": "Senores Pharma.", "full_name": "Senores Pharmaceuticals Ltd", "name_url": "stocks-analysis/senores-pharma", "exchange": 1, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "788.20", "chg": -2.9, "chgp": "-0.37%", "dir": -1, "prev_price": "791.10", "mcapval": "3,629.94 Cr", "mcap": "Small Cap", "scripcode": "544319", "symbol": "SENORES", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE0RB801010", "curr_date": "Jan 28", "curr_time": "", "bse_nse_vol": "1.7 lacs", "exc_status": "Active", "traded_date": "Jan 28, 2026", "traded_date_str": "2026 01 28", "score": "", "scoreText": "", "Live": 0, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/senores-pharma-10039497-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Senores Pharmaceuticals Gains 1.40%: 4 Key Factors Driving the Week’s Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-gains-140-4-key-factors-driving-the-weeks-moves-3802809", "imagepath": "", "date": "2026-01-24 09:00:07", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 19:</strong> Stock opens strong at Rs.806.55 (+2.06%) despite Sensex decline</p>\n <p><strong>Jan 20:</strong> Q3 FY26 results reveal robust growth but stock dips 2.90%</p>\n <p><strong>Jan 21:</strong> Intraday high of Rs.838.60 with 7.13% surge on strong financial trend</p>\n <p><strong>Jan 22:</strong> Quality grade upgraded amid strong fundamentals</p>\n <p><strong>Jan 23:</strong> Week closes at Rs.801.30, down 4.29% on profit booking</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-va..." }, { "title": "Senores Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-upgrades-quality-grade-amid-strong-financial-performance-3799439", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_qualitydot_3799439.png", "date": "2026-01-22 08:00:12", "description": "Senores Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. The company’s robust sales and EBIT growth, alongside prudent debt management and enhanced returns on capital, underpin this positive reassessment by MarketsMOJO. Investors should consider these developments in the context of the broader pharmaceuticals sector and Senores’ recent market performance." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3798108", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_mojoScore_3798108.png", "date": "2026-01-21 10:10:53", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook." }, { "title": "Senores Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Trend Amid Market Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-reports-very-positive-quarterly-financial-trend-amid-market-volatility-3797532", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_fintrenddot_3797532.png", "date": "2026-01-21 08:00:12", "description": "Senores Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a shift from an outstanding to a very positive financial trend. Despite recent market headwinds and a 2.9% decline in share price on 21 Jan 2026, the company’s robust revenue growth and margin expansion underscore its strengthening fundamentals within the Pharmaceuticals & Biotechnology sector." }, { "title": "Are Senores Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-senores-pharmaceuticals-ltd-latest-results-good-or-bad-3797022", "imagepath": "", "date": "2026-01-20 19:15:34", "description": "Senores Pharmaceuticals Ltd's latest financial results for the quarter ending December 2025 reflect a notable operational performance amidst some challenges. The company reported net sales of ₹174.56 crores, marking a sequential growth of 7.91% compared to the previous quarter, and a significant year-on-year growth of 69.44%. This robust revenue growth underscores the company's successful scaling efforts and market acceptance.\n\nIn terms of profitability, the consolidated net profit stood at ₹31.66 crores, which represents a year-on-year increase of 84.28%. However, it also indicates a slight sequential decline of 2.22% from the previous quarter. The operating margin reached 32.76%, the highest recorded for the company, reflecting improved operational efficiency and pricing power.\n\nDespite these positive trends, the financial metrics also reveal some areas of concern. The company's return on equity and retur..." }, { "title": "Senores Pharmaceuticals Q3 FY26: Robust Growth Momentum Meets Valuation Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/senores-pharmaceuticals-q3-fy26-robust-growth-momentum-meets-valuation-concerns-3796917", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_quaterlyResult_3796917.png", "date": "2026-01-20 16:18:27", "description": "Senores Pharmaceuticals Ltd., a small-cap player in India's pharmaceuticals and biotechnology sector with a market capitalisation of ₹3,691 crores, delivered another quarter of impressive growth in Q3 FY26, though the stock retreated 2.9% on January 20, 2026, to close at ₹783.15. The company reported consolidated net profit of ₹31.66 crores for the quarter ended December 2025, marking an 84.28% year-on-year surge, whilst revenue climbed 69.44% to ₹174.56 crores—the highest quarterly sales figure in the company's recent history." }, { "title": "When is the next results date for Senores Pharmaceuticals Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-senores-pharmaceuticals-ltd-3792339", "imagepath": "", "date": "2026-01-14 23:15:52", "description": "The next results date for Senores Pharmaceuticals Ltd is scheduled for 20 January 2026...." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3788023", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_mojoScore_3788023.png", "date": "2026-01-10 10:10:35", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Senores Pharmaceuticals Declines 5.86%: Key Events Shaping This Week’s Market Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-declines-586-key-events-shaping-this-weeks-market-moves-3787831", "imagepath": "", "date": "2026-01-10 09:00:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 5:</strong> New 52-week and all-time high at Rs.872.6</p>\n <p><strong>Jan 7:</strong> Fresh 52-week and all-time high at Rs.876</p>\n <p><strong>Jan 8:</strong> Sharp decline amid heavy volume</p>\n <p><strong>Jan 9:</strong> Week closes at Rs.813.40 (-0.90%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.848.60</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.813.40</div><div class=\"stat-change negative\">-5.86%</div></div>..." } ], "total": 175, "sid": "10039497", "stock_news_url": "https://www.marketsmojo.com/news/senores-pharmaceuticals-10039497" }, "announcements": "", "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Jan 19: Stock opens strong at Rs.806.55 (+2.06%) despite Sensex decline

Jan 20: Q3 FY26 results reveal robust growth but stock dips 2.90%

Jan 21: Intraday high of Rs.838.60 with 7.13% surge on strong financial trend

Jan 22: Quality grade upgraded amid strong fundamentals

Jan 23: Week closes at Rs.801.30, down 4.29% on profit booking

Week Open

Read full news article

Senores Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Performance

2026-01-22 08:00:12

Senores Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. The company’s robust sales and EBIT growth, alongside prudent debt management and enhanced returns on capital, underpin this positive reassessment by MarketsMOJO. Investors should consider these developments in the context of the broader pharmaceuticals sector and Senores’ recent market performance.

Read full news article

Senores Pharmaceuticals Ltd is Rated Hold

2026-01-21 10:10:53

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Read full news article

Senores Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Trend Amid Market Volatility

2026-01-21 08:00:12

Senores Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a shift from an outstanding to a very positive financial trend. Despite recent market headwinds and a 2.9% decline in share price on 21 Jan 2026, the company’s robust revenue growth and margin expansion underscore its strengthening fundamentals within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Senores Pharmaceuticals Ltd latest results good or bad?

2026-01-20 19:15:34

Senores Pharmaceuticals Ltd's latest financial results for the quarter ending December 2025 reflect a notable operational performance amidst some challenges. The company reported net sales of ₹174.56 crores, marking a sequential growth of 7.91% compared to the previous quarter, and a significant year-on-year growth of 69.44%. This robust revenue growth underscores the company's successful scaling efforts and market acceptance. In terms of profitability, the consolidated net profit stood at ₹31.66 crores, which represents a year-on-year increase of 84.28%. However, it also indicates a slight sequential decline of 2.22% from the previous quarter. The operating margin reached 32.76%, the highest recorded for the company, reflecting improved operational efficiency and pricing power. Despite these positive trends, the financial metrics also reveal some areas of concern. The company's return on equity and retur...

Read full news article

Senores Pharmaceuticals Q3 FY26: Robust Growth Momentum Meets Valuation Concerns

2026-01-20 16:18:27

Senores Pharmaceuticals Ltd., a small-cap player in India's pharmaceuticals and biotechnology sector with a market capitalisation of ₹3,691 crores, delivered another quarter of impressive growth in Q3 FY26, though the stock retreated 2.9% on January 20, 2026, to close at ₹783.15. The company reported consolidated net profit of ₹31.66 crores for the quarter ended December 2025, marking an 84.28% year-on-year surge, whilst revenue climbed 69.44% to ₹174.56 crores—the highest quarterly sales figure in the company's recent history.

Read full news article

When is the next results date for Senores Pharmaceuticals Ltd?

2026-01-14 23:15:52

The next results date for Senores Pharmaceuticals Ltd is scheduled for 20 January 2026....

Read full news article

Senores Pharmaceuticals Ltd is Rated Hold

2026-01-10 10:10:35

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.